The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related Child's Class A Cirrhosis  Brian L. Pearlman, Carole Ehleben, Michael Perrys  Gastroenterology  Volume 148, Issue 4, Pages 762-770.e2 (April 2015) DOI: 10.1053/j.gastro.2014.12.027 Copyright © 2015 AGA Institute Terms and Conditions

Figure 1 Virologic response rates. Overall, 93% of patients in the all-oral therapy arm achieved a sustained virologic response, which was statistically greater than the 75% of participants who achieved the same end point with the interferon-containing regimen. No statistical difference was noted between the 2 regimens when stratified by prior therapy response. Naive, had received no prior therapy for hepatitis C virus infection; Null, prior null responder to peginterferon/ribavirin; PEG/RBV/SOF, peginterferon, ribavirin, sofosbuvir; SIM-SOF, simeprevir, sofosbuvir. Gastroenterology 2015 148, 762-770.e2DOI: (10.1053/j.gastro.2014.12.027) Copyright © 2015 AGA Institute Terms and Conditions

Figure 2 Virologic response rates based on ethnicity. No statistical difference in efficacy rates were noted between African American and non-Hispanic white participants in either the all-oral therapy arm or the interferon-containing arm. PEG/RBV/SOF, peginterferon, ribavirin, sofosbuvir; SIM-SOF, simeprevir, sofosbuvir. Gastroenterology 2015 148, 762-770.e2DOI: (10.1053/j.gastro.2014.12.027) Copyright © 2015 AGA Institute Terms and Conditions

Supplementary Figure 1 Study flow diagram. A total of 134 patients were screened, and 93 patients were randomized. Four patients randomized to the all-oral therapy arm could not obtain approval for this regimen by their insurance carrier, so they could not participate in the study. Four patients randomized to the interferon-containing arm refused to be treated with interferon and therefore declined study participation, as did 3 patients who withdrew for unknown reasons. Thus, 82 patients were included in the primary, modified intention-to-treat analysis (ITT). Gastroenterology 2015 148, 762-770.e2DOI: (10.1053/j.gastro.2014.12.027) Copyright © 2015 AGA Institute Terms and Conditions